Preclinical assessment shows that betulinic acid derivatives reduce tumor size effectively in melanoma, suggesting a new therapeutic pathway.
, these derivatives led to approximately 90% tumour regression at 1.5 mg/kg when compared to the control group. These findings indicate that BA derivatives exhibit higher chemotherapeutic potential in melanoma cells than unmodified BA does.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: